MSD entered into a voluntary licensing agreement with five Indian drug makers including Sun Pharma, Cipla, Dr. Reddy’s, Emcure and Hetero for molnupiravir, an experimental drug that is currently tested to treat Covid-19 infections. Merck is running the clinical trials for molnupiravir with its partner Ridgeback Biotherapeutics.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3dYANmJ
via IFTTT
Home »
Healthcare/Biotech-Industry-Economic Times
» MSD in talks with Medicines Patent Pool for additional licenses for molnupiravir
0 comments:
Post a Comment